The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Subscribe To Our Newsletter & Stay Updated
